Brief Addiction Monitor (BAM)
Brief Addiction Monitor · Also known as: BAM
The BAM is a 17-item self-report instrument designed to provide rapid, multimodal assessment of substance use, craving, risk factors, protective factors, and psychosocial functioning in individuals receiving addiction treatment. Developed by Cacciola and colleagues in 2013, it serves as an efficient outcome monitoring tool for tracking treatment progress, identifying relapse warning signs, and guiding therapeutic adjustments. The BAM is useful in treatment settings where frequent assessment of multiple domains is needed to optimize care.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The BAM is appropriate for use during addiction treatment to monitor outcomes at regular intervals (weekly to monthly depending on treatment intensity). It is particularly useful in intensive outpatient programs (IOP), residential treatment, and medication-assisted treatment (MAT) settings where frequent monitoring is feasible and necessary. The BAM serves as a progress monitoring tool rather than a screening instrument; it should be used in individuals already engaged in treatment. It is less suitable for one-time assessment or diagnosis; use DUDIT, SADQ, or CUDIT-R for initial screening.
Strengths & limitations
- Multimodal assessment capturing substance use, craving, risk factors, protective factors, and functioning in a brief instrument
- Designed specifically for outcome monitoring during treatment, with sensitivity to detect within-person changes over time
- Includes both deficit (risk factors) and asset (protective factors) domains, aligning with strengths-based and resilience-focused care approaches
- Brief administration time (5–10 minutes) makes it feasible for frequent progress monitoring during intensive treatment
- Provides actionable clinical data across multiple domains to guide treatment adjustments and relapse prevention
- Not designed as a screening or diagnostic instrument; intended for use in individuals already identified as substance users
- Depends on self-report and may be subject to underreporting, particularly in legal or institutional contexts where honesty carries risk
- Multimodal scoring produces domain-specific rather than single composite scores, requiring interpretation across multiple dimensions
- Norms and cutoff scores are less established than for longer, extensively validated instruments
Frequently asked
How often should the BAM be administered?
The BAM is designed for frequent administration (weekly to monthly) during active treatment. Frequency depends on treatment setting: intensive outpatient programs may administer weekly; standard outpatient may administer monthly. Serial administration is more informative than single assessments.
What does a high craving score mean?
A high craving score (e.g., 7–10 on a 0–10 scale) indicates strong urges to use substances. While craving is common during recovery and does not predict relapse with certainty, persistently high craving despite treatment may indicate need for medication adjustment, intensified coping skill training, or assessment for psychiatric comorbidity.
Can the BAM be used to diagnose addiction?
No. The BAM is a progress monitoring tool for individuals in treatment, not a diagnostic instrument. Use DUDIT, SADQ, CUDIT-R, or DSM-5 criteria-based assessment for diagnostic purposes.
What if BAM scores show increasing use despite treatment attendance?
Increasing use (or craving) despite treatment engagement warrants clinical investigation and potential treatment modifications. Consider psychiatric comorbidity, inadequate medication dosing (if applicable), social stressors, trauma history, or need for more intensive psychosocial intervention. Collateral information (urinalysis, family report) should verify self-reported use.
How do I interpret declining protective factors on the BAM?
Declining protective factors (reduced support, weakened coping) indicate reduced resilience and heightened relapse risk. Therapeutic response should focus on rebuilding support networks, skill training, and addressing barriers to engagement (e.g., trauma, stigma, loss).
Is the BAM suitable for use with adolescent substance users?
The BAM was developed and validated in adult populations. Its applicability to adolescents requires adaptation and validation in age-appropriate language and item relevance. Clinicians using BAM with adolescents should consider developmental appropriateness and supplement with structured adolescent-specific assessments.
Sources
- Cacciola, J. S., Alterman, A. I., Drapkin, M. L., & Valadez, C. (2013). Development and initial validation of the Brief Addiction Monitor (BAM). Journal of Substance Abuse Treatment, 44(3), 256–263. DOI: 10.1037/t22949-000 ↗
How to cite this page
ScholarGate. (2026, June 3). Brief Addiction Monitor. ScholarGate. https://scholargate.app/en/addiction-medicine/brief-addiction-monitor
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- CUDIT-RAddiction Medicine↔ compare
- DUDITAddiction Medicine↔ compare
- ORTAddiction Medicine↔ compare
- SADQAddiction Medicine↔ compare